Organoids Serve as Viable In Vitro Model for Functional Precision Medicine for Mesonephric-Like Adenocarcinoma of the Ovary Authors: David Holthaus, Huy Duc Le, Laura Matzner, Franziska Kellers, Christoph Rogmans, Vincent Winkler, Lorenz Bastian, Stephanie Fliedner, Jörg-Paul Weimer, Hauke Busch, Tim Mandelkow, Björn Konukiewitz, Nicolai Maass, Marion van Mackelenbergh, Ibrahim Alkatout, Dirk O Bauerschlag, Nina Hedemann Published: 2026 Background Recently, a new type of ovarian carcinoma, mesonephric-like adenocarcinoma (MLA), has been recognized, accounting for less than 1% of all ovarian carcinoma cases.1 MLAs represent a rare malignant neoplasm affecting the uterine corpus and ovaries. It is hypothesized that mesonephric duct remnants persist along the lateral walls of the cervix, vagina, uterine corpus, and adnexa during embryogenesis. These duct remnants degenerate and trigger malignant transformation.2,3 In recent years, another hypothesis concerning the pathogenesis of MLAs has emerged through examination of its molecular characteristics: MLAs have similar characteristics to Müllerian-type carcinoma with secondary mesonephric differentiation.1,4 Therefore, MLAs have been included in the updated WHO Classification of Female Genital Tract Tumors in 2020.5 Pors et al3 recently presented the largest clinicopathological characterization of 25 cases of MLA: The mean age of disease onset was 61 years. Patients presented with symptoms of pelvic pain, postmenopausal bleeding, and abdominal bloating. Furthermore, 39% of patients were diagnosed at an advanced stage (International Federation of Gynecology and Obstetrics [FIGO] ≥2), with 42% of cases exhibiting disease recurrence, predominantly in distant sites.3 Currently, there are no guideline recommendations for the treatment of MLA. As with other ovarian carcinomas, cytoreductive surgery with tumor resection is recommended. The surgical procedure should include a total hysterectomy, bilateral adnexectomy, omentectomy, and pelvic lymphadenectomy. This is due to the lack of feasible alternatives and is usually followed by adjuvant chemotherapy with carboplatin and paclitaxel, as is the case of high-grade serous ovarian cancer (HGSOC).6 A challenge here is that MLA is associated with a poorer prognosis than other ovarian carcinoma subtypes as it often exhibits chemotherapeutic resistance and high recurrence rates. Functional chemotherapeutic testing, including standard-of-care platin- and taxane-based drugs, using in vitro propagated cells has been missing for this particular tumor entity. Here, we describe a rare case of ovarian MLA for which we developed organoids that were used for functional in vitro chemoresistance testing alongside molecular characterisation by whole-exome sequencing (WES) and immunohistochemistry (IHC) within the framework of the local molecular tumour board. Material and Methods A detailed summary of the Materials and Methods is given in the Data Supplement. Organoid Establishment Primary tumor cells were obtained from patients with advanced-stage ovarian cancer undergoing routine surgery (Ethical Approvals 563/21 and 631/24). Patient data are summarized in the Data Supplement (Table S4). Organoids were established following protocols from Trillsch et al.7 Ethics Approval and Consent to Participate The studies involving humans were approved by the ethical committee of the Medical Faculty of the Christian-Albrechts-Universität zu Kiel (Ethical Approvals 563/21 and 631/24). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Results Clinical Presentation A 61-year-old patient presented with a mild discomfort in the lower abdomen and increased perspiration for a duration of 3 weeks. The patient's medical history revealed no instances of cancer in her family, no preexisting conditions, and a history of nulligravida status. Vaginal ultrasound and CT scan revealed a 10 × 9 × 9 cm mass originating from the left ovary (Fig 1A). Additionally, a capsule-transgressing lesion was identified in the spleen and several potentially metastasized paracolic lymph nodes (Figs 1B and 1C). Transvaginal ultrasound revealed an 11 cm inhomogeneous pelvic mass (Fig 1D). Further investigation using laboratory analyses revealed elevated levels of tumor markers, with carbohydrate antigen 19-9 recorded at 168 kU/L and cancer-antigen-125 at 88.2 kU/L. Clinical imaging suggesting an advanced ovarian malignancy with possible splenic involvement. (A) Computed tomography cross-sectional imaging of the pelvis. Large contrast-enhancing partially solid, partly cystic mass most likely originating from the left ovary, measuring approximately 10 × 9 × 8 cm. The solid portion measures 5.5 cm. (B) A predominantly hypodense mass growing beyond the spleen capsule is visible at the splenic hilum, measuring approximately 4.3 × 3.8 cm axially. (C) Two lymph nodes suspected of metastasis paracolic on the right, measuring 10 × 7 mm and 7 × 7 mm. (D) Transvaginal ultrasound report: 11 × 8 cm cystic, inhomogeneous ovarian tumor with a 6 × 4 cm solid component, a small amount of free fluid in the pouch of Douglas, and no ascites. Given these findings, the patient underwent an exploratory laparotomy. During surgery, a tumor originating in the left ovary was found to occupy the entire minor pelvis. The right adnexa was unremarkable. The peritoneum, the colonic fossae, and the greater omentum were palpated as tumor-free. A total abdominal hysterectomy, bilateral salpingo-oopherectomy, omentectomy, splenectomy, and partial peritonectomy were performed. Intraoperative frozen section analysis confirmed the clinical suspicion of ovarian cancer, albeit of an uncertain type. No macroscopic residuals (R0) were achieved. The patient recovered well from the surgery and was able to start adjuvant chemotherapy promptly. Currently, there is no evidence of disease. The postoperative histopathologic examination revealed an MLA measuring 50 mm in size in the left ovary. Immunohistochemical analysis demonstrated the characteristic profile of MLA and is presented in the Data Supplement (Table S1). The tumor was found to be mismatch repair proficient. Histopathological examination of the spleen revealed metastases, resulting in FIGO IVb classification. Molecular testing, including BRCA1/2 DNA repair–associated gene (BRCA1/2) mutation analysis and homologous recombination deficiency testing, was initiated with results pending at the time of treatment initiation. Given the rarity of MLAs and the absence of specific evidence-based treatment guideline for this histological subtype, the decision to proceed with standard first-line chemotherapy for advanced ovarian cancer was made with the patient's agreement. The patient was started on a regimen comprising six cycles of carboplatin (AUC5), paclitaxel (175 mg/m2), and bevacizumab (15 mg/kg) every 3 weeks. This was followed by maintenance therapy with bevacizumab for a total of 15 weeks. Treatment tolerance has been acceptable, and the patient is currently completing her planned six cycles of chemotherapy. Molecular Characterization Following the surgical removal of the patient's tumor mass, samples were analyzed by WES and IHC. IHC analysis revealed positive signals for paired box gene 8 (PAX8), trefoil factor 1 (TFF1), Erb-B2 receptor tyrosine kinase 2 (ERBB2/HER2), tumor-associated calcium signal transducer 2 (TACSTD2/TROP2), PMS1 homolog 2/mismatch repair system component (PMS2), MutL protein homolog 1 (MLH1), MutS homolog 6 (MSH6), and MutS homolog 2 (MSH2); focal weak to moderate positivity for GATA binding protein 3 (GATA3); luminal positivity for membrane metalloendopeptidase (MME/CD10); and questionable weak positivity for inhibin alpha (Fig 2A, Data Supplement, Fig S1). The tumor was negative for estrogen receptor (ER/ESR1), progesterone receptor (PR/PGR), WT1 transcription factor (WT1), pan-neurotrophic receptor tyrosine kinase (NTRK), programmed death ligand 1 (PD-L1/CD274), calbindin 2/calretinin (CALB2), thyroglobulin (TG), and synaptophysin (SYN), matching earlier reports of MLAs (Fig 2A, Data Supplement, Fig S1).8 Expression of DNA mismatch repair proteins (MLH1, PMS2, MSH2, MSH6) was detectable by IHC proving MMR proficiency. Twenty percent of the tumor cells were negative for TROP2, whereas 10% were weakly, 20% moderately, and 50% strongly positive. More than 50% of the tumor cells were strongly positive for ERBB2/HER2. Zero percent of tumor cells showed membranous expression of PD-L1. Less than 1% of the tumor surface was covered by PD-L1–positive immune cells. Molecular characterization of the tumor by immunohistochemistry and whole-exome sequencing. (A) Immunohistochemical staining of paired box gene 8 (PAX8), GATA binding protein 3 (GATA3), trefoil factor 1 (TFF1), Erb-B2 receptor tyrosine kinase 2 (ERBB2/HER2), estrogen receptor (ER/ESR1), progesterone receptor (PR/PGR), and WT1 transcription factor (WT1). The tumor shows detectable expression of PAX8, TFF1, GATA3, and ERBB2/HER2 and is negative for PR, ER, and WT1 showing characteristic marker gene expression for MLA.8 Additional stainings were performed for tumor-associated calcium signal transducer 2 (TACSTD2/TROP2), pan-neurotrophic receptor tyrosine kinase (NTRK), programmed death ligand 1 (PD-L1/CD274), calbindin 2/calretinin (CALB2), inhibin alpha, thyroglobulin (TG), synaptophysin (SYN), membrane metalloendopeptidase (MME/CD10), PMS1 homolog 2/mismatch repair system component (PMS2), MutL protein homolog 1 (MLH1), MutS homolog 6 (MSH6), and MutS homolog 2 (MSH2) and are provided in the Data Supplement (Fig S1). (B) Overview of the copy-number variations identified by whole-exome sequencing via the MIRACUM pipeline.9 Large amplifications are found in chromosomes 2, 7, 10, 12, and 13. (C) Mutational summary variations identified by whole-exome sequencing via the MIRACUM pipeline.9 A total of 31 mutations were found of which two were in-frame deletion, one a frameshift deletion, one nonsense mutation, and 27 missense mutations. For molecular diagnostics, WES was performed on resected tumor samples. Large amplifications were found in chromosomes 2, 7, 10, 12, and 13 (Fig 2B). Sequencing revealed 31 mutations, of which two were in-frame deletion, one a frameshift deletion, one nonsense mutation, and 27 missense mutations (Fig 2C, Data Supplement, Table S2). Two mutations, KRAS G12V and DYNC1H1 G4072S, have been annotated as pathogenic and likely pathogenic by the in-house bioinformatic pipeline.9 Tumor mutational burden was low at 1.14 mutations/Mb. In Vitro Chemosensitivity Testing In parallel, organoids were established using previously established protocols7,10 (Fig 3A). After establishment of the organoid line, we conducted determinations of chemosensitivity and chemoresistance. For this, earlier established fallopian tube organoids were used as toxicity control11,12 (Fig 3B, dark gray), and for better comparison, three organoid lines of cases of high-grade ovarian cancer were included in the analysis (Fig 3B, light gray). HGSOC1 and HGSOC2 were relatively sensitive to the tested chemotherapeutics, whereas HGSOC3 was resistant to all them (Fig 3B and 3C). Fallopian tube organoids were used to indicate the therapeutic windows below the toxic range of chemotherapy. Cells were then treated with increasing concentrations of the standard chemotherapeutic agents cisplatin and paclitaxel, as well as poly (ADP-ribose) polymerase 1 (PARP) inhibitor olaparib, which is recommended for the treatment of patients with BRCA1/2 DNA repair–associated (BRCA1/2) mutations. Additionally, we included the mitogen-activated protein kinase 1 (MEK/MAP2K1) inhibitor binimetinib, as previous studies have reported the sensitivity of MLAs with KRAS mutations to MEK inhibition.13 Fallopian tube organoids showed intermediate resistance to all tested chemotherapeutic agents with IC50s >20 μM for cisplatin, >60 nM for paclitaxel, >40 μM for olaparib, and >4 μM for binimetinib (IC50s are summarized in the Data Supplement, Table S1). The MLA patient organoid line (Figs 3B and 3C, blue) showed high resistance to standard chemotherapeutics with an IC50 >100 μM for cisplatin, paclitaxel, and olaparib. Only MEK inhibition with binimetinib resulted in significant cytotoxicity as it showed a comparably low IC50 of 2.711 μM in comparison with other chemotherapeutics and patients. Establishment and in vitro chemosensitivity testing of organoids from the tumor sample. (A) Representative light microscopic images of the established ovarian cancer organoid cultures. (B) Determination of the chemosensitivity profile of the patient's MLA to platinum-based chemotherapy, paclitaxel, the PARP inhibitor olaparib, and the MEK inhibitor binimetinib (curves in blue). Three high-grade ovarian cancer (HGSOC1-3, light gray) organoid lines are displayed for comparison. Fallopian tube (FT1-2, dark gray) organoid cultures were used as toxicity controls. Parentheses indicate target proteins. Dose-response curves including error bars and average values are presented in the Data Supplement (Fig S2). (C) Comparison of IC50s for chemotherapeutics indicates high resistance against every tested compound except for binimetinib. Crosses indicate conditions where IC50 values could not be determined due to flat dose-response curves. A detailed summary of IC50s is provided in the Data Supplement (Table S1). Scale bars in A represent 1,000 μm (overview) and 200 μm. Brightfield images were taken using a NYONE Scientific imager and extracted using YT Software 24.7 (both SYNENTEC). Curve fitting and calculation of IC50s were performed in GraphPad Prism 10.4.0. Data show calculations from three independent replicates. MLA, mesonephric-like adenocarcinoma. Discussion Ovarian MLAs have only recently been classified as a rare type of cancer of the female reproductive system.6 Due to their novelty and rare occurrence, protocols for the generation of in vitro cellular models that would enable their use in larger studies examining targeted, personalized treatment schemes have been absent so far. The tumour described here (PAX8+, GATA3+, TFF1+, ER−, PR−, WT1−) exhibited the characteristic expression pattern of MLA marker proteins. Copy-number variations were detected in chromosomes 2, 7, 10, 12, and 13. Others report that MLAs are mainly driven genetically by alterations in KRAS/NRAS that also correspond to our observations.8 Especially, KRAS G12 mutations appear to be a common identifier.6,8,14-16 Others have described similar mutational profiles in MLAs, including mutations in APC membrane recruitment protein (AMER) and BCL6 corepressor (BCOR)17; however, these appear to be generally nonrecurrent mutations. As in our case, MLAs appear to be microsatellite-stable with low tumor mutational burden.8 More importantly, we describe for the first time the feasibility of generating organoids from ovarian MLAs for in vitro chemosensitivity testing using established methods for the generation of HGSOC organoids.7,11 In vitro chemosensitivity testing using the organoid model aligned well with the molecular profiling and existing literature. Downstream inhibition of KRAS signaling using the MEK inhibitor binimetinib appeared to be highly advantageous in comparison to standard platin- and taxane-based chemotherapy and PARP1 inhibition. In vitro testing of combination treatment with standard-of-care chemotherapy such as carboplatin and paclitaxel together with targeted small-molecule inhibitors such as binimetinib would be beneficial in future studies, provided sufficient patient material is available. The analyses described here, including sequencing, immunohistochemistry (IHC), and chemosensitivity testing, revealed resistance at both the molecular and functional levels. Despite the unfavorable profile, the patient remains disease-free to this date, although the risk of recurrence remains and requires regular clinical monitoring. ACKNOWLEDGMENT We thank Finja Grundt, Frauke Grohmann, and Catharina Verkooyen for their excellent technical support. We thank all other involved colleagues from the Department of Gynecology and Obstetrics at the University Hospital Schleswig-Holstein in Kiel for the provision of tissues. We thank Dr Reinhild Geisen and Dr Anna Willms from SYNENTEC GmbH for technical assistance with the NyOne Scientific. Huy Duc Le Employment: Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus Kiel Research Funding: Medical Faculty of Kiel University Franziska Kellers Employment: University Hospital Schleswig-Holstein Research Funding: CAU Kiel Vincent Winkler Honoraria: MSD Oncology, AstraZeneca Travel, Accommodations, Expenses: AstraZeneca, Intuitive Surgical Jörg-Paul Weimer Patents, Royalties, Other Intellectual Property: German Patent: DE10012670B42005.02.03 Patent holder: UKSH Inventor: Dr Jörg-Paul Weimer Titel: Mikrodissektion von Fluoreszenz in situ hybridisierten chromosomalen Material (FISH-MD) (Inst), German Patent: DE102004001582B42006.03.16 Patent holder: UKSH Inventor: Jörg-Paul Weimer Titel: Verfahren zur Herstellung von DNS-Sonden fürDNS-Abschnitte mit repetitiven Sequenzen (Inst) Marion van Mackelenbergh Honoraria: AstraZeneca, Amgen, Daiichi Sankyo Europe GmbH, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Jenapharm, Lilly, Menarini Group, MolecularHealth, Mylan, MSD Oncology, Novartis, Pfizer, Roche, Pierre Fabre, Seagen Travel, Accommodations, Expenses: Lilly, Gilead Sciences, Novartis, Daiichi Sankyo Europe GmbH, Roche, AstraZeneca Dirk O. Bauerschlag Consulting or Advisory Role: Abbvie, Stemline Therapeutics, AstraZeneca/Daiichi Sankyo, GlaxoSmithKline, MSD Oncology, Gilead Sciences Travel, Accommodations, Expenses: AstraZeneca/Daiichi Sankyo, Gilead Sciences No other potential conflicts of interest were reported. DISCLAIMER The funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript. SUPPORT Supported by funding from the University Hospital Schleswig-Holstein. D.H., C.R. and N.H. acknowledge funding by the University Cancer Center Schleswig-Holstein via the Twinning Grant and PHSH Shared-Campus-Awards Initiative. D.H. and N.H. thank UKSH-Gemeinsam Gutes tun! Förderstiftung des UKSH (017_2023) for funds enabling ovarian organoid cultures. H.D.L. and C.R. acknowledge funding via the UKSH Clinician Scientist program. F.K. was funded by the German Research Foundation ‘Clinician Scientist Program in Evolutionary Medicine’ (project number 413490537). D.H. and H.D.L. contributed equally to this work. PREPRINT VERSION A preprint version of this manuscript has been deposited on bioRxiv and is available at: https://doi.org/10.64898/2026.04.09.717457 DATA SHARING STATEMENT A data sharing statement provided by the authors is available with this article at DOI https://doi.org/10.1200/PO-26-00661. AUTHOR CONTRIBUTIONS Conception and design: David Holthaus, Lorenz Bastian, Jörg-Paul Weimer, Hauke Busch, Nicolai Maass, Nina Hedemann Financial support: David Holthaus, Hauke Busch, Nicolai Maass, Dirk O. Bauerschlag, Nina Hedemann Administrative support: Lorenz Bastian, Jörg-Paul Weimer, Hauke Busch, Nicolai Maass, Dirk O. Bauerschlag, Nina Hedemann Provision of study materials or patients: Christoph Rogmans, Lorenz Bastian, Stephanie Fliedner, Hauke Busch, Nicolai Maass, Ibrahim Alkatout, Dirk O. Bauerschlag, Nina Hedemann Collection and assembly of data: David Holthaus, Huy Duc Le, Franziska Kellers, Vincent Winkler, Lorenz Bastian, Stephanie Fliedner, Hauke Busch, Tim Mandelkow, Björn Konukiewitz, Marion van Mackelenbergh, Ibrahim Alkatout, Dirk O. Bauerschlag, Nina Hedemann Data analysis and interpretation: David Holthaus, Huy Duc Le, Laura Matzner, Franziska Kellers, Christoph Rogmans, Lorenz Bastian, Hauke Busch, Tim Mandelkow, Björn Konukiewitz, Marion van Mackelenbergh, Nina Hedemann Manuscript writing: All authors Final approval of manuscript: All authors Accountable for all aspects of the work: All authors AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Huy Duc Le Employment: Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus Kiel Research Funding: Medical Faculty of Kiel University Franziska Kellers Employment: University Hospital Schleswig-Holstein Research Funding: CAU Kiel Vincent Winkler Honoraria: MSD Oncology, AstraZeneca Travel, Accommodations, Expenses: AstraZeneca, Intuitive Surgical Jörg-Paul Weimer Patents, Royalties, Other Intellectual Property: German Patent: DE10012670B42005.02.03 Patent holder: UKSH Inventor: Dr Jörg-Paul Weimer Titel: Mikrodissektion von Fluoreszenz in situ hybridisierten chromosomalen Material (FISH-MD) (Inst), German Patent: DE102004001582B42006.03.16 Patent holder: UKSH Inventor: Jörg-Paul Weimer Titel: Verfahren zur Herstellung von DNS-Sonden fürDNS-Abschnitte mit repetitiven Sequenzen (Inst) Marion van Mackelenbergh Honoraria: AstraZeneca, Amgen, Daiichi Sankyo Europe GmbH, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Jenapharm, Lilly, Menarini Group, MolecularHealth, Mylan, MSD Oncology, Novartis, Pfizer, Roche, Pierre Fabre, Seagen Travel, Accommodations, Expenses: Lilly, Gilead Sciences, Novartis, Daiichi Sankyo Europe GmbH, Roche, AstraZeneca Dirk O. Bauerschlag Consulting or Advisory Role: Abbvie, Stemline Therapeutics, AstraZeneca/Daiichi Sankyo, GlaxoSmithKline, MSD Oncology, Gilead Sciences Travel, Accommodations, Expenses: AstraZeneca/Daiichi Sankyo, Gilead Sciences No other potential conflicts of interest were reported. REFERENCES Associated Data Data Availability Statement A data sharing statement provided by the authors is available with this article at DOI https://doi.org/10.1200/PO-26-00661.